After months of fatigue, dizziness, and other vague symptoms, Mary Linde persistently pushed doctors to get more testing. Then at age 55, she was diagnosed with primary myelofibrosis and the JAK2 mutation.

Mary describes the fear and uncertainty after diagnosis, wondering if she'd see her grandchildren grow up or finish her career. She was originally given a short life expectancy. However, Mary has found hope through learning about emerging therapies and treatments.

In this discussion, Mary speaks with top myelofibrosis specialists, Dr. John Mascarenhas with Mount Sinai, and Dr. Tania Jain, with Johns Hopkins Medicine, talk about the available JAK inhibitor treatments, new and emerging therapies including clinical trials and the roll of stem cell transplant.

Full story & transcript → [ Ссылка ]

Thank you to GSK and Karyopharm for their support of our patient education program!

00:00 - Myelofibrosis Clinical Trial Program Introduction
02:07 - What is Myelofibrosis?
08:07 - JAK Inhibitors
12:19 - Finding the right JAK Inhibitor for each patient.
15:56 - Clinical Trials: Single JAK Inhibitor
28:16 - Stem Cell Transplant

#myelofibrosis #rarecancer #MPN #cancerresearch #bloodcancer #cancertreatment #myeloproliferativeneoplasms #myeloproliferativeneoplasm #fightmyelofibrosis
#raredisease #bloodcancer #hematology #diagnosis #treatment #clinicaltrials #jakinhibitors #combinationtherapy #transplant #advocacy #hope #cure #research

свернуть